Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis

Jayawardana, Sahan ORCID: 0000-0001-7081-3910, Weerasuriya, Chathika K., Pelzer, Puck T., Seeley, Janet, Harris, Rebecca C., Tameris, Michele, Tait, Dereck, White, Richard G. and Asaria, Miqdad ORCID: 0000-0002-3538-4417 (2022) Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis. npj Vaccines, 7 (1). ISSN 2059-0105

Text (Feasibility of novel adult tuberculosis vaccination in South Africa) - Published Version Available under License Creative Commons Attribution. Download (620kB)

• Author
• https://www.nature.com/articles/s41541-0...

Abstract

Early trials of novel vaccines against tuberculosis (TB) in adults have suggested substantial protection against TB. However, little is known about the feasibility and affordability of rolling out such vaccines in practice. We conducted expert interviews to identify plausible vaccination implementation strategies for the novel M72/AS01 E vaccine candidate. The strategies were defined in terms of target population, coverage, vaccination schedule and delivery mode. We modelled these strategies to estimate long-term resource requirements and health benefits arising from vaccination over 2025–2050. We presented these to experts who excluded strategies that were deemed infeasible, and estimated cost-effectiveness and budget impact for each remaining strategy. The four strategies modelled combined target populations: either everyone aged 18–50, or all adults living with HIV, with delivery strategies: either a mass campaign followed by routine vaccination of 18-year olds, or two mass campaigns 10 years apart. Delivering two mass campaigns to all 18–50-year olds was found to be the most cost-effective strategy conferring the greatest net health benefit of 1.2 million DALYs averted having a probability of being cost-effective of 65–70%. This strategy required 38 million vaccine courses to be delivered at a cost of USD 507 million, reducing TB-related costs by USD 184 million while increasing ART costs by USD 79 million. A suitably designed adult TB vaccination programme built around novel TB vaccines is likely to be cost-effective and affordable given the resource and budget constraints in South Africa.

Item Type:	Article
Additional Information:	© 2022 The Author(s).
Divisions:	LSE Health Health Policy
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Date Deposited:	14 Nov 2022 12:21
Last Modified:	16 Nov 2024 23:39
URI:	http://eprints.lse.ac.uk/id/eprint/117315

Actions (login required)

View Item